Newsfeeds - Spark Newswire

5 minute read

FDA
News

Relmada Therapeutics Says RELIANCE Trial For REL-1017 Did Not Meet Primary Endpoint

Today, 2:28 AM

Company to Host Conference Call Today, December 7, 2022, at 5:00 PM ET CORAL GABLES, Fla., Dec. 7, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company

RLMD

13 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 2:28 AM

Wednesday saw 219 companies set new 52-week lows.

$APE

11 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 2:28 AM

Tuesday's session saw 167 companies set new 52-week lows.

ACHL

5 minute read

Options

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 2:28 AM

On Friday, 72 companies hit new 52-week lows.

AIP

6 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 2:28 AM

On Tuesday, 89 companies set new 52-week lows.

$APE

10 minute read

News
Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 2:28 AM

During Tuesday's trading, 160 companies set new 52-week lows.

ABSI

1 minute read

Relmada’s Trial Failure Removes Competitor Risk For This Company’s Newly Launched Depression Product

By Vandana Singh

Today, 2:28 AM

On Thursday, Relmada Therapeutics Inc (NASDAQ:RLMD) reported a failed Phase 3 Major Depressive Disorder monotherapy trial for its REL-1017. BofA analyst…

AXSM